From the Department of Surgery (S.C.S., C.M.T., S.A.Z., R.M.R.), University of California, Davis, Sacramento; Department of General Surgery (S.A.Z., R.M.R.), David Grant USAF Medical Center, Travis, California; Department of Vascular Surgery (J.J.D.), R Adams Cowley Shock Trauma Center, University of Maryland Medical System; Department of Vascular Surgery (J.J.D.), United States Air Force, Baltimore, Maryland.
J Trauma Acute Care Surg. 2021 Aug 1;91(2S Suppl 2):S56-S64. doi: 10.1097/TA.0000000000003166.
Noncompressible torso hemorrhage is a leading cause of preventable death on the battlefield. Intra-aortic balloon occlusion was first used in combat in the 1950s, but military use was rare before Operation Iraqi Freedom and Operation Enduring Freedom. During these wars, the combination of an increasing number of deployed vascular surgeons and a significant rise in deaths from hemorrhage resulted in novel adaptations of resuscitative endovascular balloon occlusion of the aorta (REBOA) technology, increasing its potential application in combat. We describe the background of REBOA development in response to a need for minimally invasive intervention for hemorrhage control and provide a detailed review of all published cases (n = 47) of REBOA use for combat casualties. The current limitations of REBOA are described, including distal ischemia and reperfusion injury, as well as ongoing research efforts to adapt REBOA for prolonged use in the austere setting.
Level V.
非压迫性躯干出血是战场上可预防死亡的主要原因。主动脉内球囊阻断术于 20 世纪 50 年代首次在战场上使用,但在伊拉克自由行动和持久自由行动之前,其在军事上的应用很少。在这些战争中,部署的血管外科医生数量不断增加,出血导致的死亡人数显著上升,这导致了复苏性血管内主动脉球囊阻断术(REBOA)技术的新适应,增加了其在战斗中的潜在应用。我们描述了 REBOA 发展的背景,以满足对微创干预控制出血的需求,并详细回顾了所有已发表的(n = 47)REBOA 用于战斗伤员的病例。描述了 REBOA 的当前局限性,包括远端缺血再灌注损伤,以及正在进行的研究努力,以适应 REBOA 在艰苦环境中的长时间使用。
V 级。